Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellular Senescence | 6 | 2024 | 105 | 3.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2024 | 105 | 2.270 |
Why?
|
| Tumor Microenvironment | 9 | 2024 | 143 | 2.090 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 319 | 1.750 |
Why?
|
| Neoplasms | 6 | 2024 | 1258 | 1.550 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 214 | 1.420 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2015 | 60 | 1.070 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 556 | 0.990 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2024 | 144 | 0.830 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 1379 | 0.820 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2024 | 348 | 0.820 |
Why?
|
| Prostatic Neoplasms | 5 | 2020 | 320 | 0.820 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 72 | 0.820 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 10 | 0.810 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2020 | 16 | 0.800 |
Why?
|
| Immunity, Innate | 2 | 2024 | 768 | 0.770 |
Why?
|
| Immunotherapy | 4 | 2024 | 235 | 0.700 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 23 | 0.690 |
Why?
|
| Cytostatic Agents | 1 | 2018 | 1 | 0.640 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 13 | 0.630 |
Why?
|
| Mice | 13 | 2024 | 10305 | 0.620 |
Why?
|
| Nanoparticles | 1 | 2024 | 499 | 0.610 |
Why?
|
| Animals | 16 | 2024 | 19717 | 0.570 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2018 | 7 | 0.550 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 27 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 405 | 0.490 |
Why?
|
| Indoles | 1 | 2015 | 102 | 0.490 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2018 | 83 | 0.490 |
Why?
|
| Mesoderm | 1 | 2015 | 84 | 0.480 |
Why?
|
| Aging | 1 | 2020 | 731 | 0.450 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 968 | 0.360 |
Why?
|
| Signal Transduction | 5 | 2024 | 2890 | 0.350 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2018 | 201 | 0.350 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 37 | 0.330 |
Why?
|
| Phenotype | 2 | 2024 | 1154 | 0.330 |
Why?
|
| Humans | 15 | 2024 | 59810 | 0.320 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 202 | 0.310 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 196 | 0.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 647 | 0.290 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 56 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 3204 | 0.270 |
Why?
|
| Mice, Transgenic | 4 | 2024 | 1225 | 0.260 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 2079 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 483 | 0.240 |
Why?
|
| Tumor Escape | 1 | 2024 | 16 | 0.240 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 14 | 0.220 |
Why?
|
| Genetic Engineering | 1 | 2024 | 112 | 0.210 |
Why?
|
| Carcinogenesis | 1 | 2024 | 118 | 0.210 |
Why?
|
| Interferon Type I | 1 | 2024 | 168 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 207 | 0.210 |
Why?
|
| Cell Proliferation | 3 | 2020 | 942 | 0.180 |
Why?
|
| Genes, ras | 1 | 2020 | 28 | 0.170 |
Why?
|
| Gene Editing | 1 | 2024 | 301 | 0.170 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 71 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2018 | 14 | 0.160 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 53 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2018 | 23 | 0.160 |
Why?
|
| Purines | 1 | 2018 | 38 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2024 | 843 | 0.160 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 2 | 0.160 |
Why?
|
| Pyridones | 1 | 2018 | 35 | 0.150 |
Why?
|
| Tissue Engineering | 1 | 2020 | 134 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 201 | 0.150 |
Why?
|
| Lung | 1 | 2023 | 838 | 0.150 |
Why?
|
| Piperazines | 1 | 2018 | 81 | 0.150 |
Why?
|
| Benzimidazoles | 1 | 2018 | 59 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 182 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 118 | 0.150 |
Why?
|
| Pyridines | 1 | 2018 | 98 | 0.150 |
Why?
|
| Macrophages | 1 | 2023 | 1008 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 170 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 584 | 0.130 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 31 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 168 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 187 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2015 | 506 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 525 | 0.120 |
Why?
|
| Blotting, Western | 1 | 2015 | 596 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 511 | 0.120 |
Why?
|
| Stem Cells | 1 | 2016 | 257 | 0.110 |
Why?
|
| Apoptosis | 1 | 2018 | 1040 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2014 | 169 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 707 | 0.100 |
Why?
|
| ras Proteins | 1 | 2012 | 78 | 0.100 |
Why?
|
| Male | 6 | 2020 | 27766 | 0.090 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1996 | 0.090 |
Why?
|
| Mutation | 1 | 2018 | 2464 | 0.090 |
Why?
|
| HMGB1 Protein | 1 | 2024 | 26 | 0.060 |
Why?
|
| Interferons | 1 | 2024 | 63 | 0.060 |
Why?
|
| Quinuclidines | 1 | 2022 | 21 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2024 | 462 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 299 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 35 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2018 | 185 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 848 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 552 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 151 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 178 | 0.030 |
Why?
|
| Arginase | 1 | 2014 | 6 | 0.030 |
Why?
|
| Anisoles | 1 | 2014 | 3 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 21 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2014 | 31 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2014 | 32 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Epithelium | 1 | 2014 | 97 | 0.030 |
Why?
|
| Prostate | 1 | 2014 | 54 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 71 | 0.030 |
Why?
|
| Female | 1 | 2015 | 31095 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2014 | 92 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2014 | 122 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 363 | 0.030 |
Why?
|
| Spleen | 1 | 2014 | 486 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 262 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2012 | 16 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 34 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 37 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 52 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 739 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 115 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2100 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 353 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 1106 | 0.020 |
Why?
|